128716-86-9

Upstream product

• 917-54-4 methyllithium 
• 128716-87-0 Trifluoro-methanesulfonic acid (2S,3S)-1-[1-[(1R,3R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-3-methoxy-cyclohexyl]-meth-(Z)-ylidene]-3-[1,3]dithian-2-yl-2-(4-methoxy-benzyloxy)-butyl ester 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 127308-75-2 (1R,5R)-5-(hydroxymethyl)-2-cyclohexen-1-ol 
• 109667-78-9 N-(4-chloro-7-oxo-6-oxabicyclo[3.2.1]octan-3-yl)acetamide 
• 127258-19-9 (1R,5R)-5<(phenylsulfonyl)methyl>-1-methoxy-2-cyclohexene 
• 127258-20-2 (1R,2R,4R)-2-methoxy-4-<(phenylsulfonyl)methyl>-1-cyclohexanol 
• 128694-56-4 ((1R,5R)-5-Methoxy-cyclohex-3-enylmethylsulfanyl)-benzene 
• 128694-59-7 (2S,3S)-3-[1,3]Dithian-2-yl-2-(4-methoxy-benzyloxy)-butan-1-ol 
• 128694-60-0 (3S,4S)-1-Benzenesulfonyl-1-[(1R,3R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-3-methoxy-cyclohexyl]-4-[1,3]dithian-2-yl-3-(4-methoxy-benzyloxy)-pentan-2-ol 
• 128694-61-1 (3S,4S)-1-Benzenesulfonyl-1-[(1R,3R,4R)-4-(tert-butyl-diphenyl-silanyloxy)-3-methoxy-cyclohexyl]-4-[1,3]dithian-2-yl-3-(4-methoxy-benzyloxy)-pentan-2-one 
• 128694-53-1 (3S,4S)-1-[(1R,3R,4R)-4-(tert-Butyl-diphenyl-silanyloxy)-3-methoxy-cyclohexyl]-4-[1,3]dithian-2-yl-3-(4-methoxy-benzyloxy)-pentan-2-one 
• 128694-54-2 ((1R,2R,4R)-4-Benzenesulfonylmethyl-2-methoxy-cyclohexyloxy)-tert-butyl-diphenyl-silane 

Downstream Products

• 158040-52-9 {(1R,2R,4R)-4-[(E)-(3S,4S)-4-[1,3]Dithian-2-yl-3-(4-methoxy-benzyloxy)-2-methyl-pent-1-enyl]-2-methoxy-cyclohexyloxy}-triisopropyl-silane 
• 129873-35-4 C₆₈H₁₃₈O₁₀Si₄ 

Relevant academic research and scientific papers

Formal total synthesis of FK506. Concise construction of the C(10)-C(34) segment via an effective coupling tactic

A formal total synthesis of the potent immunosuppressant FK506 (1) has been achieved via a concise construction of the Merck advanced intermediate (-)-2. Key features of the successful strategy include stereocontrolled σ-bond installation of the trisubsti

FK-506 SYNHETIC STUDIES. 3. AN EFFICIENT ASYMMETRIC SYNTHESIS OF THE C(24)-C(34) FRAGMENT OF FK-506, FR-900520, AND FR-900523

An efficient asymmetric synthesis of the C(24)-C(34) fragment of the FK-506 family of immunosuppressants has been achieved.